Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.74 |
| ▸ | PGR | P06401 | 7/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130614 | 0.91 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL4066726 | 0.87 | NR3C1 (0.84) | NR3C1NR3C2PGRHTR2AHTR2C | |
| SCHEMBL3125575 | 0.85 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL3127613 | 0.83 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL3128278 | 0.81 | NR3C1 (0.74) | NR3C1NR3C2PGRHTR2AHTR2C | |
| SCHEMBL6227262 | 0.80 | NR3C1 (0.67) | NR3C1NR3C2PGRHTR2AHTR2C | |
| SCHEMBL4065021 | 0.79 | NR3C1 (0.84) | NR3C1NR3C2PGR | |
| SCHEMBL13810664 | 0.79 | NR3C1 (0.86) | NR3C1NR3C2PGR | |
| SCHEMBL3571165 | 0.78 | NR3C1 (1.00) | NR3C1NR3C2PGR | |
| SCHEMBL3131877 | 0.78 | NR3C1 (1.00) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539141-B1 | 3-(SULFONAMIDOETHYL)-INDOLE DERIVATIVES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2010-07-14 | — | — | EP | claimed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | claimed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1539141-B1 | 3-(SULFONAMIDOETHYL)-INDOLE DERIVATIVES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-1539141-B1 | 3-(SULFONAMIDOETHYL)-INDOLE DERIVATIVES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.